Yahoo
Shenzhen - Delayed Quote CNY

Acrobiosystems Co.,Ltd. (301080.SZ)

96.43 +1.68 (+1.77%)
At close: November 5 at 3:04:25 PM GMT+8
Chart Range Bar
Loading chart for 301080.SZ
  • Previous Close 94.75
  • Open 97.85
  • Bid 96.26 x --
  • Ask 96.37 x --
  • Day's Range 93.58 - 101.88
  • 52 Week Range 35.87 - 141.07
  • Volume 19,879,538
  • Avg. Volume 16,678,156
  • Market Cap (intraday) 16.169B
  • Beta (5Y Monthly) 0.89
  • PE Ratio (TTM) 83.13
  • EPS (TTM) 1.16
  • Earnings Date --
  • Forward Dividend & Yield 0.60 (0.63%)
  • Ex-Dividend Date Jun 11, 2026
  • 1y Target Est 87.38

Acrobiosystems Co.,Ltd. engages in the development and manufacture of recombinant proteins, antibodies, and other biological reagents for pharmaceutical and biotechnology companies, and research institutions. It provides kits, scientific services, and other related products under the Resilient Supply, CytoPak, SAFENSURE, FLAG, Star Staining, Aneuro, ComboX, and GENPower brands. The company also offers cell therapies, gene therapies, therapeutic antibodies, antibody-drug conjugates, core reagents for infectious disease research, and solutions for metabolic and autoimmune disease drug development. In addition, it provides custom reagent, assay development, and analytical services. Further, the company is involved in general business, sales and technical services of biological products, manufacture and sells medical devices, research and development of biological reagent products, business information consulting and conference, and company testing service businesses. The company's products are used in drug screening and optimization for diseases such as cancer, autoimmune diseases, cardiovascular diseases, and infectious diseases; diagnostic reagent development and optimization; preclinical and clinical trials; and drug manufacturing processes and process control. Acrobiosystems Co.,Ltd. was founded in 2010 and is based in Beijing, China.

www.acrobiosystems.cn

926

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/5/2026, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

301080.SZ
81.47%
SSE Composite Index (000001.SS)
7.03%

1-Year Return

301080.SZ
62.38%
SSE Composite Index (000001.SS)
7.04%

3-Year Return

301080.SZ
124.87%
SSE Composite Index (000001.SS)
21.75%

5-Year Return

301080.SZ
24.84%
SSE Composite Index (000001.SS)
5.68%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY24
Revenue 146M
Earnings 30.67M
Profit Margin 21.01%

Q1

FY24

0
50M
100M
21.0%

Analyst Insights

View More

Analyst Price Targets

74.78 Low
87.38 Average
96.43 Current
110.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    18.98%

  • Return on Assets (ttm)

    3.67%

  • Return on Equity (ttm)

    7.24%

  • Revenue (ttm)

    1.03B

  • Net Income Avi to Common (ttm)

    194.73M

  • Diluted EPS (ttm)

    1.16

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.16B

  • Total Debt/Equity (mrq)

    3.95%

  • Levered Free Cash Flow (ttm)

    -100.55M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: